Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study

Area of Science:

• Ophthalmology
• Immunology
• Dermatology

Background:

• Allergic conjunctivitis is a common ocular inflammatory condition.
• Intractable cases often require novel therapeutic approaches.
• Current treatments may have limitations in efficacy or side effects.

Purpose of the Study:

• To assess the feasibility of using tacrolimus 0.03% dermatological ointment for allergic conjunctivitis.
• To evaluate the safety and tolerability of topical ocular tacrolimus.
• To determine the efficacy in patients with treatment-refractory disease.

Main Methods:

• An open-label study involving 20 patients with intractable allergic conjunctivitis.
• Tacrolimus 0.03% ointment applied to the conjunctival sac twice daily for 8 weeks.
• Standardized scoring system used to assess conjunctivitis severity; blood tacrolimus levels monitored.

Main Results:

• Significant reduction in conjunctivitis severity scores observed (p < 0.001).
• Treatment was well-tolerated, with only one patient experiencing local burning and discontinuing therapy.
• Blood tacrolimus levels were predominantly undetectable, suggesting minimal systemic absorption.

Conclusions:

• Topical ocular application of tacrolimus 0.03% ointment is a feasible treatment option.
• It demonstrates effectiveness and good tolerability for allergic conjunctivitis refractory to standard treatments.
• This approach offers a potentially safe alternative for managing severe ocular allergies.